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Imaging glutathione depletion 
in the rat brain using ascorbate-
derived hyperpolarized MR and PET 
probes
Hecong Qin  1,2, Valerie N. Carroll1, Renuka Sriram1, Javier E. Villanueva-Meyer1, 
 Cornelius von Morze  1, Zhen Jane Wang1, Christopher A. Mutch1, Kayvan R. Keshari3,4,5, 
Robert R. Flavell  1, John Kurhanewicz1,2 & David M. Wilson1
Oxidative stress is a critical feature of several common neurologic disorders. The brain is well adapted 
to neutralize oxidative injury by maintaining a high steady-state concentration of small-molecule 
intracellular antioxidants including glutathione in astrocytes and ascorbic acid in neurons. Ascorbate-
derived imaging probes for hyperpolarized 13C magnetic resonance spectroscopy and positron emission 
tomography have been used to study redox changes (antioxidant depletion and reactive oxygen 
species accumulation) in vivo. In this study, we applied these imaging probes to the normal rat brain 
and a rat model of glutathione depletion. We first studied hyperpolarized [1-13C]dehydroascorbate in 
the normal rat brain, demonstrating its robust conversion to [1-13C]vitamin C, consistent with rapid 
transport of the oxidized form across the blood-brain barrier. We next showed that the kinetic rate of 
this conversion decreased by nearly 50% after glutathione depletion by diethyl maleate treatment. 
Finally, we showed that dehydroascorbate labeled for positron emission tomography, namely [1-11C]
dehydroascorbate, showed no change in brain signal accumulation after diethyl maleate treatment. 
These results suggest that hyperpolarized [1-13C]dehydroascorbate may be used to non-invasively 
detect oxidative stress in common disorders of the brain.
Reactive oxygen species (ROS) are expected products of oxidative metabolism, and must be tightly regu-
lated in the normal brain. Several pathways are required to maintain redox homeostasis, in particular the 
glutathione-glutaredoxin and thioredoxin-thioredoxin reductase systems1. These systems maintain high 
steady-state concentrations of small-molecule antioxidants including reduced glutathione (GSH) and vitamin C 
(VitC). Glial cells harbor a high concentration (in the mM range) of GSH, while neurons capture the majority of 
the VitC in the central neural system2,3. Although the reasons for this partitioning are only partially understood, 
these antioxidants are considered critical in both health and disease. Oxidative stress, marked by increased ROS 
production and GSH consumption, is implicated in various neurodegenerative and neuropsychiatric disorders 
such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and schizophrenia4,5. Therefore, non-invasive 
evaluation of brain antioxidants could provide critical insights into these disease processes.
The relationship between VitC and its oxidized counterpart dehydroascorbic acid (DHA) has been extensively 
studied. In contrast to VitC, which is slowly imported via sodium-dependent vitamin C transporter-2 (SVCT-2) 
and maintained at high steady-state concentrations in the brain6, DHA is a transient species with remarkably 
different transport properties despite its structural similarity to VitC. DHA readily crosses the blood-brain bar-
rier (BBB), actively transported by glucose transporters (GLUTs) as shown in Fig. 1a7–9. Once transported into 
cells, DHA undergoes a GSH-dependent, two-electron reduction to VitC, catalyzed by redox enzymes including 
glutaredoxin, omega-class glutathione transferases and protein-disulfide isomerase10–13. This GSH-dependent 
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conversion is one of the motivations for studying ascorbate-derived imaging agents, whose interconversion 
depends on both the concentration of GSH and the presence or absence of reactive oxygen species14,15. In particu-
lar, [1-13C]DHA, a 13C enriched version of dehydroascorbic acid, has been studied with hyperpolarized (HP) 13C 
magnetic resonance (MR) in preclinical models of cancer, diabetes, acute kidney injury, and fatty liver disease15–20. 
In addition, ascorbates labeled for positron emission tomography (PET), namely [1-11C]DHA and [1-11C]VitC, 
have recently been synthesized and studied in ROS-producing immune cells in vitro21. Together, these studies 
suggest that ascorbate-derived imaging methods may be able to image oxidative stress in vivo. In particular, 
DHA-derived imaging agents were designed to image intracellular redox capacity, typically defined as the con-
centration of intracellular reducing equivalents and the ability to regenerate them. We therefore compared these 
methodologies in an animal model of pharmacologic glutathione depletion, to determine if ascorbate-derived HP 
MR or PET probes could detect the modulation of redox capacity.
Although [1-13C]DHA and [1-11C]DHA are chemically and biochemically equivalent, the techniques used to 
study them in vivo are considerably different. HP 13C MR via dissolution dynamic nuclear polarization (dDNP) 
is an emerging imaging technology that allows direct visualization of metabolic conversion of 13C-enriched mol-
ecules, and has been applied extensively to study metabolism in cells, tissues, animal models, and patients22–24. 
dDNP transfers polarization from electron spins to 13C nuclei spins at extreme low temperature (0.8–1.3 °K) 
through microwave irradiation, providing more than 10,000-fold MR signal enhancement of 13C-labelled sub-
strates25. The HP substrate can be subsequently injected into a living system and its conversion to other metab-
olites can be monitored by MR spectroscopy in a rapid, real-time manner. HP MR with [1-13C]DHA takes 
advantage of the chemical shift between [1-13C]DHA and [1-13C]VitC (3.8 ppm) and the drastic signal enhance-
ment (~10% polarization, >104-fold at 3 Tesla) provided by dDNP to enable in vivo interrogation of redox capac-
ity. Since the hyperpolarized signal lifetime is prescribed by the T1 of the substrate (approximately 57 s for [1-13C]
DHA at 3 Tesla), HP 13C signal can be observed in vivo for approximately 1 to 2 minutes at most23. Therefore, the 
real-time detection of [1-13C]DHA to [1-13C]VitC in vivo is primarily a kinetic measurement that depends on 
substrate transport and the availability of intracellular reducing equivalents.
In contrast, PET is an established metabolic imaging technology whereby a positron-emitting isotope, such as 
11C or 18F, is incorporated into a drug or metabolite of interest, and usually imaged following a significant delay 
depending on the half-life of the radioactive isotope. Therefore, the primary determinants of image contrast are 
the transport and retention/entrapment of the radiopharmaceutical, and the clearance of nonspecific signal. As 
shown in Fig. 1b, PET images of rat brains demonstrated the distinctive difference in accumulated signal between 
[1-11C]DHA and [1-11C]VitC, as previously reported, reflecting their differential transport across the blood-brain 
barrier and cellular membrane21. In the case of [1-11C]DHA, the radiopharmaceutical is expected to be entrapped 
inside the cell once it is reduced to [1-11C]VitC, a charged molecule at physiological pH, and unreacted [1-11C]
DHA may be washed out. We hypothesized that retention of [1-11C]DHA would depend partially on intracellular 
reducing agents including GSH26, and therefore may also be modulated following glutathione-depletion.
In this study, we aimed to characterize ascorbate-derived HP 13C MR and 11C PET probes for brain imaging, 
and take advantage of their different capabilities to assess in vivo redox capacity of the rat brain. First, we studied 
the transport, compartmentalization, and biodistribution of both DHA and VitC in normal rat brain with HP 13C 
Figure 1. Ascorbates as redox imaging probes. (a) Dehydroascorbate (DHA) can traverse the blood-brain-
barrier, enter cells via glucose transporter (GLUT)1,3,4 and be rapidly reduced to ascorbic acid (vitamin C, 
VitC) by intracellular antioxidants including glutathione (GSH), which is coupled with the pentose phosphate 
pathway via NADPH. The conversion from hyperpolarized [1-13C]DHA to [1-13C]VitC can be monitored by 
MR spectroscopy, taking advantage of their unique chemical shifts. The C1 position of DHA and VitC can also 
be labelled with 11C for PET and biodistribution studies. (b) In these PET images (adapted from Carroll et al.21), 
the accumulation of [1-11C]DHA in the normal rat brain is compared to that of [1-11C]VitC in the normal rat 
brain. In normal rats, higher brain signal for [1-11C]DHA is expected since it readily crosses the blood-brain 
barrier and is transported into cells via GLUT transporters. In contrast, transport of VitC into the brain via 
sodium-dependent vitamin C transporter-2 (SVCT2) is a slower process. Unlike measuring the real-time 
conversion rate by hyperpolarized MR, PET and biodistribution with [11C]ascorbates measures the uptake and 
retention of 11C radiopharmaceuticals.
www.nature.com/scientificreports/
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MR and 11C PET probes. Then we modulated GSH content in rats by pharmacological treatment and studied the 
changes in DHA to VitC conversion in the brain using both HP 13C MR and 11C PET probes. Specifically, four 
groups of Sprague-Dawley rats were studied using: (1) two-dimensional (2D) chemical shift imaging (CSI) with 
HP [1-13C]DHA and [1-13C]VitC separately to determine the transport and compartmentalization of ascorbates 
in the head region (n = 6 for DHA, n = 3 for VitC); (2) one-dimensional (1D) slice-selective dynamic spectros-
copy with HP [1-13C]DHA, at 24 hours before and 2 hours after diethyl maleate (DEM) intraperitoneal injec-
tion (4.6 mmol/kg)27, to measure the real-time DHA to VitC conversion rate (n = 4); (3) biodistribution using 
[1-11C]DHA and [1-11C]VitC, respectively, to determine the accumulation of ascorbate-derived probes in the 
brain and other organs (n = 3 each); (4) biodistribution with [1-11C]DHA in rats with DEM treatment as in group 
(2) to measure 11C probe accumulation following glutathione depletion (n = 3). Additionally, 1D slice-selective 
dynamic spectroscopy with HP [1-13C]DHA at 60% concentration of group (2) was performed to demonstrate 
DHA to VitC reaction order (n = 3), and an in vitro GSH assay was performed on brain tissues collected from 
normal and DEM-treated rats to validate the redox modulation by DEM (n = 7 each).
Results
Behavior of HP 13C DHA and VitC in vivo is consistent with known features of blood-brain bar-
rier penetration and transport. Both HP [1-13C]DHA and HP [1-13C]VitC were administered separately 
to normal rats (group 1). Following HP [1-13C]DHA injection, its reduction to [1-13C]VitC was observed in the 
brain, demonstrated by the presence of a new downfield resonance (approximate 3.8ppm) in the 13C MR spec-
trum (n = 6). For HP [1-13C]DHA study, the DHA resonance was observed in most tissue voxels including brain 
and its surrounding tissues (muscle and vasculature), while the VitC metabolite was only observed in the brain 
voxels (Fig. 2a) with VitC/(DHA + VitC) = 0.48 ± 0.15 (estimated from 18 brain voxels), consistent with pene-
tration of DHA across the blood-brain barrier. In contrast, when HP VitC is injected, the 2D CSI (n = 3) found 
drastically lower VitC signal in the brain (mostly below quantification limit) than in surrounding tissues and no 
oxidation to DHA (Fig. 2b). These data are consistent with the slower transport of VitC across the blood-brain 
barrier, and the high reducing capacity of the normal brain8.
Glutathione depletion via diethyl maleate results in a lower rate of DHA-to-VitC conversion. 
Using a 1D dynamic HP [1-13C]DHA study, we investigated whether the DHA to VitC conversion rate is cor-
related with GSH content in the rat brain (group 2). We adopted a variable flip angle scheme to account for the 
non-renewable nature of hyperpolarized signal and to utilize signal-to-noise ratio (SNR) efficiently since the T1 
of [1-13C]VitC is relatively short (29.1 s, in vitro at 3 T)16. Dynamic spectra of the rat brain showed that the [1-13C]
Figure 2. 2D Chemical Shift Imaging with hyperpolarized 13C ascorbates reveals different transport and 
compartmentalization of dehydroascorbate (DHA) and vitamin C (VitC). (a) Injection of hyperpolarized 
[1-13C]DHA, with conversion to VitC in the normal rat brain. The VitC resonance is only observed in voxels 
corresponding to the brain as shown in the VitC signal intensity map and slab spectra, while the DHA 
resonance is observed both in the brain and surrounding tissue. A representative voxel corresponding to brain 
tissue shows both a resonance corresponding to the introduced hyperpolarized [1-13C]DHA and its metabolite 
[1-13C]VitC. (b) Injection of hyperpolarized [1-13C]VitC in normal rats. Lower (in this case negligible) VitC 
signal is seen in voxels corresponding to brain as shown in the VitC signal intensity map and slab spectra, and 
no oxidation to DHA is observed. A representative voxel corresponding to tissues in the neck show a resonance 
corresponding to the introduced hyperpolarized [1-13C]VitC without evidence of metabolic conversion.
www.nature.com/scientificreports/
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VitC signal gradually increases during the acquisition window used (Fig. 3), suggesting VitC production rate is 
greater than signal decay rate mediated by T1 relaxation. Because VitC signal is mainly from in the brain while 
DHA signal is from both the brain and surrounding tissues in the 1D slab spectra, we focused our analysis on 
the kinetic rates of VitC production as opposed to including both DHA and VitC in the kinetic model or using 
ratiometric approach.
We found the apparent VitC production rate (kapp) decreased by nearly 40% from 6.94 ± 1.52 s−1 to 
4.03 ± 2.83 s−1 (p = 0.0293) after DEM treatment (Fig. 4a). The apparent in vivo T1 of VitC was estimated to be 
7.80 ± 1.28 s (n = 9) using a subset of data (3 datasets were excluded due to poor fitting quality), and we found 
kinetic rate (k) decreased by nearly 50% from 14.15 ± 2.93 s−1 to 7.48 ± 1.80 s−1 (p = 0.0218) after DEM treatment 
(Fig. 4b). Correspondingly, the in vitro GSH assay (methods reported in the supplementary information) showed 
that brain GSH content in the DEM-treated rats is significantly lower than in the control rats (5.99 ± 0.64 vs. 
12.31 ± 0.75 μmol/g protein, n = 7, p < 0.0001) (Fig. 4c).
To validate our kinetic modeling of the DHA to VitC conversion, dynamic 1D spectroscopy was performed 
on a separate cohort of rats (n = 3) with 18 μmoles HP DHA (approximately 60% dose of the control/baseline 
group). We found there was no statistically significant difference between the control/baseline group and lower 
dose group in kapp (4.94 ± 1.04 vs. 4.38 ± 0.70 s−1, p = 0.678), or k (11.22 ± 1.74 vs. 0.94 ± 1.86 s−1, p = 0.917) as 
well as the sum of VitC signal (510.3 ± 65.06 vs. 507.6 ± 73.94 A.U., p = 0.9792) (Fig. 4d–g), suggesting that DHA 
dose used in our experimental set-up was in excess and not a rate limiting factor for VitC production.
11C Biodistribution studies showed expected differences between [1-11C]DHA and [1-11C]VitC, 
but no effect of diethyl maleate treatment on [1-11C]DHA brain accumulation. The biodistri-
bution of [1-11C]DHA or [1-11C]VitC was compared by ex vivo biodistribution analysis on harvested normal 
rat tissues 1 hour following administration (group 3, n = 3 each). In addition, [1-11C]DHA was administrated to 
DEM-treated rats (group 4, n = 3) to study the effect of GSH content on 11C radiopharmaceutical accumulation. 
Biodistribution of 11C radiopharmaceutical in three groups of rats are shown in Fig. 5. [1-11C]VitC showed lower 
uptake/retention in the brain than [1-11C]DHA (0.25 ± 0.012 vs. 0.49 ± 0.075% Injection Dose(ID)/g, p = 0.0330), 
consistent with our HP MR observations and our previously reported PET imaging study (Fig. 1b). However, lung 
and liver showed significantly higher uptake/retention for [1-11C]VitC than [1-11C]DHA (lungs: 2.10 ± 0.12 vs. 
0.42 ± 0.066%ID/g, p = 0.0002; liver: 3.57 ± 0.30 vs. 2.12 ± 0.39%ID/g, p = 0.0408). For the glutathione modula-
tion study using [1-11C]DHA, no significant difference was found in radiopharmaceutical accumulation for major 
organs between control and DEM-treated subjects (0.49 ± 0.075 vs. 0.62 ± 0.14%ID/g, p = 0.449).
Figure 3. Dynamic 1D slice-selective spectroscopy reveals real-time hyperpolarized [1-13C]dehydroascorbate 
(DHA) to [1-13C]vitamin C (VitC) conversion. MR spectra of a normal rat brain is shown in (a), and signal-
to-noise ratio quantification of DHA, VitC, and urea phantom (solid line), as well as variable flip angle (VFA) 
scheme (dash line), are plotted in (b). Hyperpolarized [1-13C]VitC signal in a normal rat brain gradually 
increases over time despite the rapid longitudinal relaxation (in vitro T1 ~ 29.2 s at 3 Tesla), and hyperpolarized 
[1-13C]DHA signal gradually decreases due to metabolic conversion and longitudinal relaxation (in vitro 
T1 ~ 56.5 s at 3 Tesla). Signal corresponding to the [13C]urea phantom (placed next to the rat head) also 
gradually increases, demonstrating the VFA scheme. A sagittal T2-weighted image demonstrates the imaging 
slab (green highlighted region).
www.nature.com/scientificreports/
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Discussion
Non-invasive in vivo evaluation of brain redox capacity and oxidative stress could provide insights into neurolog-
ical disease progression and therapeutic response. In this study, we used ascorbate-based imaging probes to study 
brain redox capacity leveraging both HP-MR and PET modalities. We first demonstrated that HP [1-13C]DHA is 
readily converted to HP [1-13C]VitC in the normal brain, evidenced by 2D chemical shift imaging revealing both 
DHA and VitC resonances in voxels corresponding to brain tissues following [1-13C]DHA injection. This finding 
is consistent with the penetration of DHA through BBB and its rapid entry into cells. In contrast, when HP [1-13C]
VitC was administered, lower hyperpolarized signal was seen in brain voxels and no oxidation to HP [1-13C]DHA 
was observed. These findings reflect the slow cellular transport process of VitC via SVCT2 against a concentration 
Figure 4. Glutathione depletion via diethyl maleate (DEM) results in a significantly lower rate of [1-13C]
dehydroascorbate (DHA) to [1-13C]vitamin C (VitC) conversion. Both apparent VitC production rate (kapp) and 
kinetic rate (k) of VitC production in the brain decreased significantly after DEM treatment (a,b), consistent 
with significantly lower brain GSH content in DEM-treated rats compared to control rats (c). To demonstrate 
DHA to VitC reaction order, 1D spectroscopy was performed on a separate cohort of rats with HP [1-13C]DHA 
at 60% of the usual dose. The average signal of [1-13C]DHA and [1-13C]VitC at each time point were plotted (d), 
and VitC signal appears unchanged with decreased DHA dose. The resulting kapp, k, and total 13C VitC SNR are 
not significantly different from the control group (e,f,g). (*p < 0.05, ****p < 0.0001).
Figure 5. Biodistribution studies reveal different accumulation of [1-11C]dehydroascorbate (DHA) and [1-11C]
vitamin C (VitC) in normal rat brain, but no effect of diethyl maleate (DEM) treatment. Gamma counting of 
harvested brains showed a significantly higher signal accumulation for [1-11C]DHA than [1-11C]VitC in the 
normal brain 1 hour following radiopharmaceutical administration. In addition, there was significantly higher 
uptake/retention for [1-11C]VitC versus [1-11C]DHA in the lungs and liver in normal rats. In the DEM-treated 
rats with [1-11C]DHA, no significant differences were found in 11C radiopharmaceutical uptake/retention 
between normal and DEM-treated rats in major organs, including the brain. (*p < 0.05, ***p < 0.001).
www.nature.com/scientificreports/
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gradient, and the role of VitC as an antioxidant reservoir that is not easily oxidized. These features represent the 
major shortcomings of [1-13C]VitC as a HP MR probe for imaging the brain.
After characterizing the transport and compartmentalization of DHA and VitC, we modulated GSH content 
with DEM treatment which depletes GSH by direct conjugation27, and studied the changes in DHA to VitC 
kinetic rates using dynamic HP 13C MR spectroscopy. 2D CSI with radiometric quantification has lower repro-
ducibility due to sensitivity to small differences in acquisition timing and substrate delivery, demonstrated by the 
variabilities in VitC/DHA ratios in 6 normal rats (reported in Supporting Information). Therefore, we adopted 
1D slab dynamic acquisition approach with variable flip angle scheme for efficient SNR usage, which is impor-
tant given the short T1 of [1-13C]VitC, to study the effect of redox modulation. In dynamic spectra of normal 
brain, there was observable real-time production of VitC; we also observed that DHA signal is about 5 times 
higher than VitC signal, suggesting that cellular transport and/or enzyme and cofactor turnover rate are likely 
rate-limiting factors for the observed VitC production. In other words, these data suggested that the DHA dose 
was in excess and not a rate-limiting factor in our experimental set-up. To demonstrate the reaction order, we 
performed dynamic spectroscopy with lower (60%) doses of [1-13C]DHA and found that the kinetic rates of VitC 
production and sum of VitC SNR are independent of DHA concentration, which validated the pseudo-zero-order 
kinetic model. To quantify in vivo reaction kinetics, we generated two kinetic parameters (reported in Methods 
section): apparent VitC production rate (kapp) is a straightforward parameter that reflects the rate of product 
accumulation, assuming T1 relaxation equally affects the control and DEM-treated groups; whereas kinetic rate 
(k) was generated by non-linear fitting and takes account of T1 relaxation. We found that DHA to VitC conversion 
rate correlated with the brain GSH content, as evidenced by significantly reduced kinetic parameters (kapp and k) 
after DEM treatment that depletes GSH by more than 50%.
There are several important considerations and limitations of our dynamic [1-13C]DHA MR study. First, each 
animal was subjected to two intravenous injections of [1-13C]DHA, an oxidant that could deplete GSH, 24 hours 
apart between baseline and post-DEM-treatment imaging12. However, Weber et al. have demonstrated that rat 
brain GSH content returns to normal 24 hours after DEM treatment, a prototypical GSH deleting agent that 
directly conjugates with GSH and is more potent than DHA27. Furthermore, depletion of GSH by DHA could 
induce increases in other intracellular reducing equivalents (such as thioredoxins) whose pool size would be 
expected to impact the rate of DHA to VitC reduction. Timm et al. have shown that DHA administration resulted 
in a rapid increase in GSSG/GSH ratio and pentose phosphate pathway (PPP) flux in cells and tumors20. It can be 
argued that the initial DHA administration for baseline imaging could upregulate PPP flux and other reducing 
equivalents, which would be a confounding factor for our study. Nevertheless, the DEM treatment seemed to 
offset the increase in PPP flux and other reducing equivalents as the VitC production rate decreased significantly. 
Second, the supraphysiologic concentration of administered HP [1-13C]DHA could saturate the transporter or 
relevant enzymes and create a rate-limiting condition, or result in substrate inhibition and decrease of enzy-
matic flux. Third, unlike the first-order reaction model, the kinetic parameters generated from pseudo-zero-order 
model are highly influenced by the numerical scale (i.e. SNR), which could potentially explain the inter-subject 
variability. For this reason, our dynamic acquisition and analysis scheme could only detect the relative changes in 
GSH content, but not the absolute concentration.
Another important consideration is the physiologic effect of DEM treatment in rats. We noted that rats 
became lethargic after DEM treatment. Numerous studies have explored the potential toxic effects of DEM in 
the heart and lung, and the dose we used was approximately 40% of the LD50 reported for oral administration to 
rats28–31. We also observed that the total 13C SNR was approximately 35% lower on average in DEM-treated than 
normal rats despite similar DNP solid state buildup, suggesting less HP 13C substrate was delivered to the imaging 
slab. Although we have demonstrated that the rate of VitC production is independent of DHA dose administered 
in our supraphysiologic dose range, it is still possible that lower DHA substrate delivery contributed to the lower 
VitC production rate.
In addition to ascorbate-derived probes designed for HP MR, we also leverage 11C radiopharmaceuticals, 
namely [1-11C]DHA and [1-11C]VitC, to study the uptake and biodistribution of ascorbates. [1-11C]VitC showed 
lower accumulation than [1-11C]DHA in the brain, consistent with HP 13C MR findings and previously reported 
PET imaging data21, but higher retention in the lung and liver 1 hour after administration, possibly due to high 
expression of sodium-depended vitamin C transporters (SVCT) in these tissues32–34. [1-11C]DHA reduction to 
[1-11C]VitC represents a potential trapping mechanism21,26, with unreduced [1-11C]DHA likely washed out of 
the cell. In the DEM redox modulation study using [1-11C]DHA, we initially hypothesized that the lower brain 
GSH content in DEM-treated cannot adequately reduce [1-11C]DHA to [1-11C]VitC, and un-reacted [1-11C]DHA 
would be washed out resulting less [1-11C]VitC retention (lower gamma counting). However, there was no dif-
ference in 11C radiopharmaceutical retention rate in major organs between the normal and DEM-treated groups.
There are several important differences between HP 13C MR and 11C biodistribution studies that could explain 
the inconsistency between their findings. As discussed in Methods section, 11C radiopharmaceuticals were 
administrated at a considerably lower pharmacologic dose compared to HP 13C probes (0.16μmol vs. 30μmol). 
It is possible that residual GSH in DEM-treated rats is adequate to reduce the lower pharmacologic dose of DHA 
used in 11C studies. More importantly, the two technologies differ significantly in their mechanisms of generating 
image contrast and timing, making direct comparison of data difficult. Biodistribution studies were performed at 
1 hour after DHA administration as compared to the 1 minute kinetic analysis applied to HP MR studies. Hence, 
it appears that although [1-11C]VitC was likely generated at a slower rate in GSH-depleted animals, there was 
insufficient washout of unreacted [1-11C]DHA to yield observable differences in 11C accumulation. It is possible 
that dynamic PET imaging or biodistribution studies by gamma counting at earlier time points could reveal sub-
tle differences in the radiopharmaceutical accumulation rate in the brain. Overall, our results suggested that the 
[1-11C]DHA was insensitive to changes in redox capacity in this pharmacologic GSH depletion model using our 
www.nature.com/scientificreports/
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experiment set-up. This highlights the potential value in studying real-time substrate conversion by HP MR as 
opposed to probe retention rate by biodistribution of radiopharmaceutical or PET imaging analysis.
In conclusion, we demonstrated the transport and biodistribution features of DHA and VitC in the brain by 
both HP 13C MR and 11C PET probes, and found that the kinetic rates of [1-13C]DHA to [1-13C]VitC conversion 
correlated with brain GSH content. These studies suggest that hyperpolarized [1-13C]DHA can assess brain redox 
capacity non-invasively, and potentially allow visualization of oxidative stress in numerous brain pathologies.
Methods
Dynamic Nuclear Polarization (DNP). Both [1-13C]DHA and [1-13C]VitC were prepared, polarized, 
and dissolved in aqueous media as previously described14. A 2.2 M solution of [1-13C]DHA dimer (Sigma 
Aldrich ISOTEC, Miamisburg, OH) in dimethyacetamide (DMA) containing 15 mM OX063 trityl radical (GE 
Healthcare, Menlo Park, CA) was polarized on a HyperSense DNP instrument (Oxford Instruments, Abingdon, 
UK) operating at 3.35 Tesla and 1.3°K, achieving approximately 10% polarization after 1 hour microwave irra-
diation (determined by separate NMR studies using the same material). The frozen sample was then rapidly 
dissolved in distilled water containing 0.3 mM ethylenediaminetetracetic acid (EDTA) with a final concentra-
tion of 15–22 mM and pH of 5.5. For all in vivo studies, approximately 30 μmoles of [1-13C]DHA (1.3–2.0 ml) 
were administered intravenously to rats. Similarly, a 2.2 M solution of [1-13C]VitC (Omicron Biochemicals, South 
Bend, IN) was prepared as a sodium salt in NaOH/water/DMSO, polarized, and dissolved in 100 mM phosphate 
buffer to a final pH of 7.0. For 2D CSI studies, approximately 100 μmoles of HP [1-13C]VitC were administered 
intravenously.
11C radiopharmaceutical synthesis. [1-11C]VitC were synthesized from L-xylosone and [11C]HCN 
precursors using a GE PETtrace cyclotron at our on-site radiopharmaceutical facility as previously described21 
and reported in the supplementary information. Overall, [1-11C]VitC was obtained with a decay-corrected radi-
ochemical yield of 35.8 ± 18% and a specific activity of 1.7 ± 0.4 mCi/μmol (n = 3). [1-11C]DHA was obtained 
by oxidation of [1-11C]VitC with a decay-corrected radiochemical yield of 25.8 ± 2.6% and a specific activity of 
1.85 ± 0.5 mCi/μmol (n = 6).
MR studies. All animal experiments were approved by our Institutional Animal Care and Use Committee 
(IACUC) and performed in accordance with IACUC protocols. Rats were placed under 1.5–2% isoflurane anes-
thesia and administered 30 μmoles HP [1-13C]DHA or 100 μmoles HP [1-13C]VitC solution via tail-vein catheter 
for both 2D CSI studies and dynamic 1D spectroscopy. For group (1) rats (n = 6 for DHA and n = 3 for VitC), 
two-dimensional single time-point CSI was performed on a GE Signa 3 Tesla MR scanner using a dual-tuned 1H-
13C coil with the following parameters: voxel size = 5 × 5 × 20 mm, TE/TR = 135/210 ms, flip angle = 20°, spec-
tral bandwidth/resolution = 5000/9.77 Hz, and 25 s acquisition delay after the start of injection. For group (2) 
rats, one-dimensional slice-selective dynamic spectroscopy with HP [1-13C]DHA was performed using a similar 
set-up on a GE Signa 3 Telsa (n = 2 before and after DEM treatment) and a Bruker Biospec 3 Tesla MR scanner 
(n = 3 before DEM treatment, n = 2 after DEM treatment, n = 3 for 60% dose experiments), with the following 
parameters: spectral bandwidth/resolution = 25 kHz/12.2 Hz, slice thickness = 10 mm, TR = 2 s, 10 repetitions, 
RF-compensated variable flip angle scheme35,36, and 25 s acquisition delay after the start of injection. Axial and 
sagittal T2-weighted anatomic images were acquired with a fast spin echo sequence prior to HP 13C studies and 
used to prescribe the spectroscopy slab. Rats were fasted for 8 hours before HP 13C MR studies to reduce glucose 
competition with DHA for GLUTs as previously reported14,17,37.
11C biodistribution studies. Rats were placed under 1.5–2% isoflurane anesthesia and administered 
304 ± 78 μCi [1-11C]DHA or 360 ± 180  μCi [1-11C]VitC via tail vein catheters (for group 3 and 4 rats). Animals 
were subsequently sacrificed at 1 hour after radiopharmaceutical injection, and internalized radioactivity was 
immediately measured on their harvested organs using a Hidex automatic gamma counter (Turku, Finland) 
(n = 3 each).
Data analysis. 2D CSI data was reconstructed and overlaid on axial anatomic images using SIVIC38; the 
peak heights of DHA and VitC resonances were manually quantified on the magnitude spectrum. The metabolite 
ratio, VitC/(DHA + VitC), was calculated for each voxel. For 1D dynamic MR spectroscopy data, SNRs of DHA 
and VitC resonances for each time point were quantified based on the fit peak integral in MestreNova12 (Madrid, 
Spain), and were subsequently used to generate kinetic parameters in MATLAB 2017b (Natick, MA). We demon-
strated that the DHA to VitC conversion in this experiment was a pseudo-zero-order reaction as shown in Results 
section, and generated two kinetic parameters based on a zero-order kinetic model assuming no back conversion 
from VitC to DHA: (1) apparent VitC production rate (kapp) via linear fitting of VitC signal and normalized to 
total VitC SNR, and (2) kinetic rate (k) via non-linear least square fitting of VitC signal with the Trust-Region 
algorithm to the following equations:
= +
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dt
k
T
M1
(1)
z
z
1
θ θ
=
∏ =
−M
M
sin( ) cos( ) (2)
z n
xy n
n i
n
i
,
,
1
1
where Mz is longitudinal magnetization, Mxy is transverse magnetization (observed signal), n is the index of time 
points, and θ = −N narctan(1/ )n is the flip angle. Dynamic data was first fit into kinetic models with T1 as an 
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unknown parameter to estimate apparent in vivo T1 of VitC, which was subsequently incorporated into the kinetic 
model as a fixed parameter to generate k assuming T1 is the same across the subjects. Apparent kinetic rate (kapp) 
reflects the rate of observed VitC signal change caused by both T1 relaxation and VitC production from DHA, 
while k reflects only the VitC production rate.
A paired Student’s t-test was used to compare kinetic parameters before and after DEM treatment. An 
unpaired Student’s t-test was used to compare the GSH content of rat brains with and without DEM treatment 
and biodistribution of [1-11C]ascorbates. All statistical analyses were performed using GraphPad Prism 7d (La 
Jolla, CA). All quantitative results are reported and graphed as mean ± standard deviation; p values < 0.05 were 
considered statistically significant, and our p values for biodistribution analysis were not adjusted for multiple 
comparisons.
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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